Compare PDLB & GLSI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | PDLB | GLSI |
|---|---|---|
| Founded | 1960 | 2006 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 401.0M | 372.0M |
| IPO Year | 2021 | 2020 |
| Metric | PDLB | GLSI |
|---|---|---|
| Price | $17.51 | $27.10 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $50.00 |
| AVG Volume (30 Days) | 50.9K | ★ 112.6K |
| Earning Date | 04-24-2026 | 05-19-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 160.87 | N/A |
| EPS | ★ 1.20 | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $14.62 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $10.88 | $7.78 |
| 52 Week High | $18.01 | $34.10 |
| Indicator | PDLB | GLSI |
|---|---|---|
| Relative Strength Index (RSI) | 63.33 | 56.21 |
| Support Level | $15.84 | $21.20 |
| Resistance Level | $18.01 | $30.02 |
| Average True Range (ATR) | 0.37 | 1.88 |
| MACD | 0.05 | 0.42 |
| Stochastic Oscillator | 72.22 | 86.22 |
Ponce Financial Group Inc, is a United States-based holding company. Its business consists of taking deposits from the general public and investing those deposits, together with funds generated from operations, in mortgage loans, consisting of one-to-four-family residential, multi-family residential, non-residential property and construction and land, and, to a lesser extent, business, and consumer loans. The company also invests in securities, which consists of securities issued by the U.S. Government and federal agencies and mortgage-backed securities issued by the United States government-sponsored enterprises. Some of the products and services include checking solutions, online and mobile banking, merchant credit card services, and others.
Greenwich LifeSciences Inc a clinical-stage biopharmaceutical company focused on its Phase III clinical trial, Flamingo-01, which is evaluating GLSI-100, an immunotherapy to prevent breast cancer recurrences. GP2 is a 9 amino acid transmembrane peptide of the HER2/neu protein, a cell surface receptor protein that is expressed in a variety of common cancers, including expression in 75 percent of breast cancers at low (1+), intermediate (2+), and high (3+ or over-expressor) levels. The combination of GP2 + GM-CSF is called GLSI-100. The company is currently expanding Flamingo-01 into Europe with plans to open up to 150 sites globally.